Heat shock proteins in cancer: targeting the ‘chaperones’

References

• 1  Richter K, Haselbeck M, Buchner J. The heat shock response: life on the verge of death. Mol. Cell40(2),253–266 (2010).
  Medline CASGoogle Scholar
• 2  Almeida M, Nascimento JL, Herculano AM, Crespo-Lopez ME. Molecular chaperones: toward new therapeutic tools. Biomed. Pharmacother.65,239–243 (2011).
  Medline CASGoogle Scholar
• 3  Young D, Agashe VR, Siegers K, Hartl F. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol.5,781–791 (2004).
  Medline CASGoogle Scholar
• 4  Wang W, Vinocur B, Shoseyov O, Altman A. Role of plant heat-shock proteins and molecular chaperones in the abiotic stress response. Trends Plant Sci.9(5),244–252 (2004).
  Medline CASGoogle Scholar
• 5  Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol.146(6),769–780 (2005).
  Medline CASGoogle Scholar
• 6  Laudanski K, Wyczechowska D. The distinctive role of small heat shockproteins in oncogenesis. Arch. Immunol. Ther. Exp. (Warsz).54(2),103–111 (2006).
  Medline CASGoogle Scholar
• 7  Wegele H, Muller L, Buchner J. Hsp70 and Hsp90 – a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol.151,1–44 (2004).
  Medline CASGoogle Scholar
• 8  Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem.75,271–294 (2006).
  Medline CASGoogle Scholar
• 9  Bruey JM, Ducasse C, Bonniaud P et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol.2,645–652 (2000).
  Medline CASGoogle Scholar
• 10  Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle5,2592–2601 (2006).
  Medline CASGoogle Scholar
• 11  Ravagnan L, Gurbuxani S, Susin SA et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat. Cell Biol.3,839–843 (2001).
  Medline CASGoogle Scholar
• 12  Lanneau D, de Thonel A, Maurel S, Didelot C, Garrido C. Apoptosis versus cell differentiation: role of heat shock proteins Hsp90, Hsp70 and Hsp27. Prion1(1),53–60 (2007).
  MedlineGoogle Scholar
• 13  Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell130(6),1005–1018 (2007).
  Medline CASGoogle Scholar
• 14  Bagatell R, Paine-Murrieta GD, Taylor CW et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin. Can. Res.6(8),3312–3318 (2000).
  Medline CASGoogle Scholar
• 15  Baler R, Zou J, Voellmy R. Evidence for a role of Hsp70 in the regulation of the heat shock response in mammalian cells. Cell Stress Chaperones1(1),33–39 (1996).
  Medline CASGoogle Scholar
• 16  Mosser DD, Duchaine J, Massie B. The DNA-binding activity of the human heat shock transcription factor is regulated in vivo by Hsp70. Mol. Cell. Biol.13(9),5427–5438 (1993).
  Medline CASGoogle Scholar
• 17  Cheng L, Hirst K, Piper PW. Authentic temperature-regulation of a heat shock gene inserted into yeast on a high copy number vector. Influences of overexpression of Hsp90 protein on high temperature growth and thermotolerance. Biochim. Biophys. Acta1132(1),26–34 (1992).
  Medline CASGoogle Scholar
• 18  Hjorth-Sorensen B, Hoffmann ER, Lissin NM, Sewell AK, Jakobsen BK. Activation of heat shock transcription factor in yeast is not influenced by the levels of expression of heat shock proteins. Mol. Microbiol.39(4),914–923 (2001).
  Medline CASGoogle Scholar
• 19  Soti C, Csermely P. Aging and molecular chaperones. Exp. Gerontol.38(10),1037–1040 (2003).
  Medline CASGoogle Scholar
• 20  Harris N, MacLean M, Hatzianthis K, Panaretou B, Piper PW. Increasing Saccharomyces cerevisiae stress resistance, through the overactivation of the heat shock response resulting from defects in the Hsp90 chaperone, does not extend replicative life span but can be associated with slower chronological aging of nondividing cells. Mol. Genet. Genomics265(2),258–263 (2001).
  Medline CASGoogle Scholar
• 21  Hooper PL. Hot-tub therapy for Type 2 diabetes mellitus. N. Engl. J. Med.341(12),924–925 (1999).
  Medline CASGoogle Scholar
• 22  Hooper PL, Hooper PL. Inflammation, heat shock proteins, and Type 2 diabetes. Cell Stress Chaperones14(2),113–115 (2009).
  Medline CASGoogle Scholar
• 23  Romanucci M, Bastow T,Della Salda L. Heat shock proteins in animal neoplasms and human tumors – a comparison. Cell Stress Chaperones13(3),253–262 (2008).
  Medline CASGoogle Scholar
• 24  Sankhala KK, Mita MM, Mita AC, Takimoto CH. Heat shock proteins: a potential anticancer target. Curr. Drug Targets12(14),2001–2008 (2011).
  Medline CASGoogle Scholar
• 25  Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones10(2),86–103 (2005).
  Medline CASGoogle Scholar
• 26  Soo ET, Yip GW, Lwin ZM, Kumar SD, Bay BH. Heat shock proteins as novel therapeutic targets in cancer. In Vivo22(3),311–315 (2008).
  Medline CASGoogle Scholar
• 27  Calderwood SK, Khaleque MA, Sawyer DB, CioccaDR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci.31(3),164–172 (2006).
  Medline CASGoogle Scholar
• 28  Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med.228(2),111–133 (2003).
  Medline CASGoogle Scholar
• 29  Shiota M, Kusakabe H, Yzumi Y, et al. Heat shock cognate protein 70 is essential for Akt signaling in endothelial function. Arterioscler. Thromb. Vasc. Biol.30(3),491–497 (2010).
  Medline CASGoogle Scholar
• 30  Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J. Natl Cancer Inst.85,1558–1570 (1993).
  Medline CASGoogle Scholar
• 31  Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle5,2592–2601 (2006).
  Medline CASGoogle Scholar
• 32  Takayama S, Reed JCand Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene22,9041–9047 (2003).
  Medline CASGoogle Scholar
• 33  Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic Hsp90 complex in cancer. Nat. Rev. Cancer.10(8),537–549 (2010).
  Medline CASGoogle Scholar
• 34  Eiseman JL, Lan J, Lagattuta TF et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2- dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol.55,21–32 (2005).
  Medline CASGoogle Scholar
• 35  Chandarlapaty S, Scaltriti M, Angelini P et al. Inhibitors of Hsp90 block p95-HER2 signaling in trastuzumab-resistant tumors and suppress their growth. Oncogene29,325–334 (2010).
  Medline CASGoogle Scholar
• 36  Kim YS, Alarcon SV, Lee S et al. Update of Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem.9(15),1479–1492 (2009).
  Medline CASGoogle Scholar
• 37  Landriscina M, Amoroso MR, Piscazzi A, Esposito F. Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol. Oncol.117(2),177–182 (2010).
  Medline CASGoogle Scholar
• 38  Sreedhar AS, Kalmár E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett.562,11–15 (2004).
  MedlineGoogle Scholar
• 39  McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell131,121–135 (2007).
  Medline CASGoogle Scholar
• 40  Eustace BK, Sakurai T, Stewart JK et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol.6,507–514 (2004).
  Medline CASGoogle Scholar
• 41  Whitesell L, Lindquist SL. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer5,761–772 (2005).
  Medline CASGoogle Scholar
• 42  Pick E, Kluger Y, Giltnane JM et al. High Hsp90 expression is associated with decreased survival in breast cancer. Cancer Res.67,2932–2937 (2007).
  Medline CASGoogle Scholar
• 43  Price JT, Quinn JM, Sims NA et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res.65,4929–4938 (2005).
  Medline CASGoogle Scholar
• 44  Roe S, Prodromou C, O’Brien R,Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by antitumor antibiotic radicicol and geldanamycin. J. Med. Chem.42(2),260–266 (1999).
  Medline CASGoogle Scholar
• 45  Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol.36,305–315 (1995).
  Medline CASGoogle Scholar
• 46  Stebbins CE, Russo AA, Schneider C et al. Crystal structure of an Hsp90–geldanamycin complex. Cell89(2),239–250 (1997).
  Medline CASGoogle Scholar
• 47  Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide binding pocket. Curr. Med. Chem.15(26),2702–2717 (2009).
  Google Scholar
• 48  Lancet E, Gojo I, Burton M et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia24,699–705 (2010).
  Medline CASGoogle Scholar
• 49  Kummar S, Gutierrez ME, Gardner ER et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer46,340–347 (2010).
  Medline CASGoogle Scholar
• 50  Hanson BE, Vesole DH. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin. Investig. Drugs18,1375–1383 (2009).
  Medline CASGoogle Scholar
• 51  Shelton S.N. Shawgo ME, Matthews SB et al. A novel Novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol.76(6),1314–1322 (2009).
  Medline CASGoogle Scholar
• 52  Lundgren K, Zhang H, Brekken J et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol. Cancer Ther.8,921–929 (2009).
  Medline CASGoogle Scholar
• 53  Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int. J. Cancer126,1216–1225 (2010).
  Medline CASGoogle Scholar
• 54  Zhang H, Neely L, Lundgren K et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int. J. Cancer126,1226–1234 (2010).
  Medline CASGoogle Scholar
• 55  Elfiky A, Saif MW, Beeram M et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. J. Clin. Oncol.26,127–129 (2008).
  MedlineGoogle Scholar
• 56  Cerchietti LC, Lopes EC, Yang SN et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6 dependent B cell lymphomas. Nat. Med.15(12),1369–1376 (2009).
  Medline CASGoogle Scholar
• 57  Sharp SY, Prodromou C, Boxall K et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylicpyrazole/isoxazole amide analogues. Mol. Cancer Ther.6,1198–1211 (2007).
  Medline CASGoogle Scholar
• 58  Eccles SA, Massey A, Raynaud FI et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res.68,2850–2860 (2008).
  Medline CASGoogle Scholar
• 59  Jensen MR, Schoepfer J, Radimerski T et al. NVP-AUY922: a small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res.10(2),R33 (2008).
  MedlineGoogle Scholar
• 60  Chandarlapaty S, Sawai A, Ye Q et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res.14,240–248 (2008).
  Medline CASGoogle Scholar
• 61  Wang Y, Trepel JB, Neckers LM, Giaccone G. STA-9090, a small-mulecule Hsp90 inhibitor for the potential treatment of cancer. Curr. Opin. Investig. Drugs.11(12),1466–1476 (2010).
  Medline CASGoogle Scholar
• 62  Proia DA, Foley KP, Korbut T et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS ONE6(4),e18552 (2011).
  Medline CASGoogle Scholar
• 63  Yu MK, Samlowski WE, Baichwal V. MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4–8 June 2010.
  Google Scholar
• 64  Young JC, Barral JM, Ulrich Hartl F. More than folding: localized functions of cytosolic chaperones. Trends Biochem. Sci.28,541–547 (2003).
  Medline CASGoogle Scholar
• 65  Chiang HL, Terlecky SR, Plant CP, Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science246,382–385 (1989).
  Medline CASGoogle Scholar
• 66  Galluzzi L, Giordanetto F, Kroeme G. Targeting Hsp70 for cancer therapy. Mol. Cell.36(2),176–177 (2009).
  Medline CASGoogle Scholar
• 67  Pei H, Zhu H, Zeng S, Li Y, Yang H. Proteome analysis and tissue micro array for profiling protein markers associated with lymph node metastasis in colorectal cancer. J. Proteome Res.6(7),2495–2501 (2007).
  Medline CASGoogle Scholar
• 68  Jaattela M. Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int. J. Cancer60,689–693 (1995).
  Medline CASGoogle Scholar
• 69  Brondani Da Rocha A, Regner A, Grivicich I et al. Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines. Int. J. Oncol.25,777–785 (2004).
  Medline CASGoogle Scholar
• 70  Schmitt E, Parcellier A, Gurbuxani S et al. Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res.63,8233–8240 (2003).
  Medline CASGoogle Scholar
• 71  Gabai VL, Meriin AB, Yaglom JA, Volloch VZ, Sherman MY. Role of Hsp70 in regulation of stress-kinase JNK: implications in apoptosis and aging. FEBS Lett.438,1–4 (1998).
  Medline CASGoogle Scholar
• 72  Bottoni P, Giardina B, Scatena R. Proteomic profiling of heat shock proteins: an emerging molecular approach with direct pathophysiological and clinical implications. Proteomics Clin Appl.3,636–653 (2009).
  Medline CASGoogle Scholar
• 73  Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and Hsp72 inhibits Hsp90 function and induces tumor-specific apoptosis. Cancer Cell.14,250–262 (2008).
  Medline CASGoogle Scholar
• 74  Powers MV, Clarke PA, Workman P. Death by chaperone,Hsp90, Hsp70 or both? Cell Cycle8,518–526 (2009).
  Medline CASGoogle Scholar
• 75  Braunstein MJ, Scott SS,Scott CM et al.Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3–101. J. Oncol.201,232037 (2011).
  Google Scholar
• 76  Parcellier A, Schmitt E, Gurbuxani S et al. Hsp27 is a ubiquitin-binding protein involved in I-κBα proteasomal degradation. Mol. Cell. Biol.23,5790–5802 (2003).
  Medline CASGoogle Scholar
• 77  Rocchi P, Kojima S, Signaevsky M et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res.64,6595–6602 (2004).
  Medline CASGoogle Scholar
• 78  Garrido C, Fromentin A, Bonnotte B et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res.58,5495–5499 (1998).
  Medline CASGoogle Scholar
• 79  Williams K, Chubb C, Huberman E, Giometti CS. Analysis of differential protein expression in normal and neoplastic human breast epithelial cell lines. Electrophoresis.19,333–343 (1998).
  Medline CASGoogle Scholar
• 80  Mori-Iwamoto S, Kuramitsu Y, Ryozawa S et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol.31,1345–1350 (2007).
  Medline CASGoogle Scholar
• 81  Choi DH, Ha JS, Lee WH et al. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett.581,1649–1656 (2007).
  Medline CASGoogle Scholar
• 82  Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SA. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res. Treat.56,187–196 (1999).
  Medline CASGoogle Scholar
• 83  Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by Hsp90 (Hsp90 complex) that forms a stress-sensitive complex with HSF1. Cell94,471–480 (1998).
  Medline CASGoogle Scholar
• 84  Piper PW, MillsonSH. Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges. Pharmaceuticals4,1400–1422 (2011).
  Medline CASGoogle Scholar
• 85  Davenport EL, Zeisig A, Aronson LI et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia24,1804–1807 (2010).
  Medline CASGoogle Scholar
• 86  Rossi A, Ciafrè S, Balsamo M, Pierimarchi P, Santoro MG. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res.66(15),7678–7685 (2006).
  Medline CASGoogle Scholar
• 87  Murshid A, Chou SD, Prince T, Zhang Y, Bharti A, Calderwood SK. Protein kinase A binds and activates heat shock factor 1. PLoS ONE5,e13830 (2010).
  MedlineGoogle Scholar
• 88  Akerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nat. Rev. Mol Cell. Biol.11,545–555 (2010).
  Medline CASGoogle Scholar
• 89  Kang BH, Altieri DC. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene28,3681–3688 (2009).
  Medline CASGoogle Scholar
• 90  Kang BH, Plescia J, Song HY et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest.119(3),454–464 (2009).
  Medline CASGoogle Scholar
• 91  Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature425,407–410 (2003).
  Medline CASGoogle Scholar
• 92  Gallo LI, Lagadari M, Piwien-Pilipuk G, Galigniana MD. The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress. J. Biol. Chem.286(34),30152–30160 (2011).
  Medline CASGoogle Scholar
• 93  Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol.81,15–27 (2007).
  Medline CASGoogle Scholar
• 94  Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res.9,3235–3245 (2003).
  Medline CASGoogle Scholar
• 95  Castelli C, Rivoltini L, Rini F et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol. Immunother.53,227–233 (2004).
  Medline CASGoogle Scholar